Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial

Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial

Abstract Advanced biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC) have poor prognoses and limited treatment options. Here, we conducted this first-in-class phase II study to evaluate the efficacy and safety of SHR-1701, a bifunctional fusion protein targeting programmed death-...

Full description

Saved in:
Bibliographic Details
Main Authors: Lixia Yi, Haoqi Pan, Zhouyu Ning, Litao Xu, Hena Zhang, Longfei Peng, Yaowu Liu, Yifan Yang, Waimei Si, Ying Wang, Xiaoyan Zhu, Shenglin Huang, Zhiqiang Meng, Jing Xie
Format: Article
Language:English
Published: Nature Publishing Group 2024-12-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-024-02052-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-024-02052-3

Similar Items